Scientific Review of Azacitidine (5-AzaC)
Status: Listed in the Report on Carcinogens (RoC)
Primary Uses or Exposures: 5-AzaC is an antineoplastic agent that has been used as an investigational drug for the treatment of patients with acute myeloblastic anemia, acute lymphoblastic leukemia, and myelodysplastic syndromes.
No Public Comments
- NTP Board of Scientific Counselors RoC Subcommittee Meeting (November 18–19, 1996)
Note on Accessibility: Persons with disabilities or using assistive technology may find some documents are not fully accessible. For assistance, contact Central Data Management or use our form and identify the documents/pages for which access is required. We will assist you in accessing the content of these files. NIEHS has helpful information on accessibility.